New findings support the routine use of remdesivir in hospitalized COVID-19 patients

Remdesivir, an antiviral drug used to treat COVID-19, increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study authored by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, HCA Healthcare, and Genospace.

The researchers analyzed data from over 43,000 patients hospitalized with COVID-19 and treated by HCA Healthcare. Patients who received remdesivir were matched to the most similar patients in a control group whose members were eligible for, but did not receive, remdesivir treatment. Overall, 74% of remdesivir-receiving patients saw improvement within 28 days (with a median time of seven days) versus 68.3% of control patients (with a median time of nine days).

In particular, remdesivir patients receiving low-flow oxygen treatment or no treatment with oxygen saw significantly greater clinical improvement than their control patient counterparts. Treatment with remdesivir also significantly reduced mortality in patients on low-flow oxygen, even when accounting for the effects of anti-inflammatory medications, such as dexamethasone. Of these patients on low-flow oxygen, the 28-day mortality rate of remdesivir recipients was 4.1% lower than that of the control patients.

Our findings support the routine use of remdesivir in patients who are hospitalized with COVID-19. We observed that remdesivir is best used as early as possible, before the patient progresses to requiring high levels of oxygen or intubation and mechanical ventilation. Most patients who need that kind of advanced respiratory support are likely past the point where antiviral therapies like remdesivir would be effective."

Brian Garibaldi, M.D., study lead author, associate professor of medicine, Johns Hopkins University School of Medicine

There have been several previous studies on remdesivir's effectiveness in treating COVID-19 infection, and the results have often conflicted. However, the authors of this study have great confidence in their conclusions due to the diversity of the patients evaluated and the fact that this is one of the largest retrospective studies of remdesivir to date.

"This is an important, real-world study that shows remdesivir does work in many cases," says Garibaldi. "Our findings are particularly important as we battle a surge of delta and omicron cases. By using remdesivir to shorten the length of the illness, we can free up hospital beds for COVID and non-COVID patients, and alleviate capacity issues across the country."

The study was conducted as part of the COVID-19 Consortium of HCA Healthcare and Academia for Research Generation (CHARGE), a partnership between HCA Healthcare, the Agency for Healthcare Research and Quality, and 10 academic medical centers (including the Johns Hopkins University School of Medicine) across the United States. CHARGE uses data derived from HCA Healthcare's vast clinical network that has cared for close to 200,000 U.S. patients hospitalized with COVID-19. This public-private partnership serves as a unique opportunity to learn about COVID-19, as well as a potential model for future big data collaborations that can drive discovery for numerous other diseases.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
The longitudinal progression of health outcomes in COVID-19 survivors with different initial disease severity